- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04925063
The Effect of Metformin in Patients With Newly Diagnosed mHSPC
A Prospective, Randomized Trial Comparing Metformin Plus Androgen Deprivation Therapy (ADT) and Abiraterone With ADT Plus Abiraterone in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Metastatic hormone-sensitive prostate cancer (mHSPC) can be treated with androgen-deprivation therapy (ADT) alone, ADT plus abiraterone, ADT plus enzalutamide, ADT plus apalutamide, ADT plus docetaxel. However, most patients eventually progress to castration-resistant prostate cancer (CRPC) and die of the disease. Therefore, there is still a need to improve the therapeutic effect for mHSPC.
Many studies have shown that metabolic syndrome and its components are associated with increased development and progression of aggressive prostate cancer. Metformin, a common well-tolerated oral biguanide prescribed for type II diabetes, could be used to decrease the risk of prostate cancer development and improve the efficacy of treatment. Some studies reported that metformin could enhance the effectiveness of ADT, and improve recurrence-free survival, overall survival and cancer-specific survival. A prospective randomized study reported that metformin potentially lengthen time to CRPC in advanced prostate cancer patients when combined with ADT especially in those with high risk localized prostate cancer, clinically node positive and in those with low tumor volume metastatic hormone-sensitive patients.
After extensive research, there is no published results from prospective randomized trials evaluating the effect of metformin in combination with ADT and abiraterone among patients with newly diagnosed mHSPC.
Studietype
Inschrijving (Verwacht)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Yonghong Li, M.D.
- Telefoonnummer: 86-13711376697
- E-mail: liyongh@sysucc.org.cn
Studie Contact Back-up
- Naam: Zhenyu Yang, M.D.
- Telefoonnummer: 86-13902290670
- E-mail: yangzy@sysucc.org.cn
Studie Locaties
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen University Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Histologically confirmed and newly diagnosed metastatic hormone-sensitive adenocarcinoma of the prostate without small cell carcinoma or small cell components.
- Metastatic adenocarcinoma of the prostate proved by imaging (CT/MRI and/or bone scan).
- Patient must give written informed consent before registration and prior to any trial related investigations.
- Age ≥18 years.
- Serum potassium ≥3.5mmol/ L.
- ECOG performance status 0-2
- Ongoing androgen deprivation therapy with drugs or bilateral orchiectomy, and continuous abiraterone plus prednisone.
- Patient agrees not to father a child during participation in the trial and during 3 months thereafter.
- Patient agrees not to participate other interventional trials.
- Patients are able to swallow study drug as whole tablet.
Exclusion Criteria:
- Diagnosed diabetes or fasting blood-glucose ≥ 6.1mmol/L, or glycosylated hemoglobin ≥ 5.6%.
- Previous malignancy within 2 years prior to randomization, with the exception of localized non-melanoma skin cancer and Ta bladder cancer.
Prior treatment for prostate cancer with drugs, radiotherapy and surgery, with the exception below:
- ADT within 3 months before randomization, and no evidence of progression.
- Palliative radiotherapy or surgery for metastases due to symptoms, at least 4 weeks before randomization.
- Major surgery within 4 weeks prior to randomization.
- Treatments with 5a-reductase inhibitors, estrogen, cyproterone acetate, and androgen within 4 weeks prior to randomization.
- Known or suspected Central nervous system CNS metastases or active leptomeningeal disease.
- Equivalent dosage of >5mg/day prednisone of glucocorticoids for the treatment of prostate cancer within 4 weeks prior to randomization, or treatment with glucocorticoids for other reasons.
- Prior treatment for prostate cancer with flutamide, bicalutamide, ketoconazole, abiraterone, enzalutamide, apalutamide, docetaxel chemotherapy, or other interventional drugs for prostate cancer.
- Neutrophils < 1.5 x 109/L, platelets < 75 x 109/L, hemoglobin < 100 g/L.
- ALT and AST ≥ 2.5 x ULN, bilirubin ≥ 1.5 x ULN.
- eGFR<45 ml/min/1.73m2.
- Allergic to metformin or any ingredients of this tablet.
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
- Albumin< 30 g/L.
Clinically significant cardiovascular disease including:
- Myocardial infarction within 6 months prior to randomization.
- Uncontrolled angina within 3 months prior to registration.
- Congestive heart failure NYHA class III or IV.
- History of clinically significant ventricular arrhythmias (e.g. ventricular tachycardia, ventricular fibrillation, torsades de pointes).
- History of Mobitz II second or third degree heart block without a permanent pacemaker in place.
- Systolic pressure< 86 mmHg.
- Bradycardia, heart rate<45/min.
- Uncontrolled hypertension as indicated by systolic blood pressure > 170 mmHg OR diastolic blood pressure > 105 mmHg.
- ADT with or without anti-androgens more than 3 months prior to randomization.
- Prior treatment with metformin after diagnosis of prostate cancer.
- Allergic to metformin or any drugs used in this trial.
- Serious underlying medical condition (at the judgment of the investigator) which could impair the ability of the patient to participate in the trial (e.g. uncontrolled or acute severe infection, uncontrolled diabetes).
- Active or symptomatic viral hepatitis or chronic liver disease.
- History of pituitary or adrenal dysfunction.
- Gastrointestinal disorder affecting absorption.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Metformin+ADT+abiraterone
Drug: Metformin The starting daily dose of metformin is 500mg once daily, to be increased to 2000mg once daily if tolerated until disease progression Drug: Abiraterone Abiraterone 1000mg once daily until disease progression
|
The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated.
Metformin will be continued until disease progression.
Andere namen:
|
Geen tussenkomst: ADT+abiraterone
Drug: Abiraterone Abiraterone 1000mg once daily until disease progression
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Castration-resistant prostate cancer free survival
Tijdsspanne: 5 years
|
Duration from randomization to time till development of CRPC (Castration-resistant prostate cancer).
CRPC is defined by disease progression despite castration level of testosterone and may present as either a biochemical progression and/or radiological progression.
|
5 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Overall Survival
Tijdsspanne: 5 years
|
Overall survival is defined from randomization until death due to any reason.
|
5 years
|
Radiographic progression-free survival
Tijdsspanne: 5 years
|
Radiographic progression-free survival is defined from randomization until radiographic progression.
|
5 years
|
Safety
Tijdsspanne: 5 years
|
Adverse events will be assessed according to NCI-CTC AE 5.0.
|
5 years
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2021-FXY-078
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Uitgezaaide prostaatkanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Nog niet aan het wervenAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op Metformin
-
Tan Tock Seng HospitalWerving
-
Brian ZuckerbraunVoltooidOntstekingsreactieVerenigde Staten
-
Poznan University of Medical SciencesUniversity of California, San DiegoOnbekend
-
Mahidol UniversityMinistry of Health, ThailandWervingTuberculose, longThailand
-
Beni-Suef UniversityVoltooid
-
SINA Health Education and Welfare TrustVoltooidPolycysteus ovarium syndroom | Gewichtstoename | HbA1cPakistan
-
Cairo UniversityOnbekendMetaboolsyndroom | Nierinsufficiëntie | Diabetestype 2Egypte
-
Beni-Suef UniversityMinia UniversityVoltooidDiabetes mellitus, type 2Egypte
-
German University in CairoWerving